Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12875742 | 0.98 | HTR2A (0.50) | HTR2AHTR2CHTR2BMDM2SLC9A1 | |
| SCHEMBL26407935 | 0.79 | MDM2 (0.47) | HTR2AHTR2CHTR2BMDM2SLC9A1 | |
| Ammonia Solution, Strong SCHEMBL7928878 | 0.76 | KDM1A (0.58) | HTR2AHTR2CHTR2BSLC9A1SLC6A3 | |
| Ammonia Solution, Strong SCHEMBL268752 | 0.76 | KDM1A (0.52) | LMNA | |
| SCHEMBL20408752 | 0.76 | HTR2A (0.40) | HTR2AHTR2CHTR2BMDM2SLC9A1 | |
| SCHEMBL8130407 | 0.76 | MDM2 (0.45) | HTR2AHTR2CHTR2BMDM2SLC6A3 | |
| SCHEMBL13847886 | 0.76 | HTR2A (0.42) | HTR2AHTR2CHTR2BMDM2SLC6A3 | |
| SCHEMBL13379961 | 0.76 | HTR2A (0.42) | HTR2AHTR2CHTR2BMDM2SLC6A3 | |
| SCHEMBL3673574 | 0.75 | HTR2A (0.52) | HTR2AHTR2CHTR2BSLC6A3SLC6A2 | |
| Ammonia Solution, Strong SCHEMBL266310 | 0.75 | MAOB (0.54) | HTR2AHTR2CHTR2BSLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431378-B2 | Aminotransferase, gene encoding the same, and methods of using them | KANEKA CORPORATION (JP) | 2013-04-30 | — | — | US | disclosed |
| US-20120164724-A1 | NOVEL AMINOTRANSFERASE, GENE ENCODING THE SAME, AND METHODS OF USING THEM | KANEKA CORPORATION (JP) | 2012-06-28 | — | — | US | disclosed |
| US-8133705-B2 | Aminotransferase, gene encoding the same, and method of using them | KANEKA CORPORATION (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20100285544-A1 | Novel aminotransferase, gene encoding the same, and method of using them | KANEKA CORPORATION (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-1889907-B1 | NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME | KANEKA CORP (JP) | 2009-09-02 | — | — | EP | disclosed |
| EP-1889907-A1 | NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME | Kaneka Corporation (JP) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100285544-A1 | Novel aminotransferase, gene encoding the same, and method of using them | BCAT1, AGXT, ALDH7A1 | HTR2A 4765/4885HTR2C 4788/4885HTR2B 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.